Detlef Schuppan

Summary

Publications

  1. doi request reprint Anti-fibrotic therapy: lost in translation?
    Detlef Schuppan
    Division of Molecular and Translational Medicine, Dept of Medicine I, University of Mainz Medical School, Mainz, Germany
    J Hepatol 56:S66-74. 2012
  2. doi request reprint Non-celiac wheat sensitivity: differential diagnosis, triggers and implications
    Detlef Schuppan
    Institute for Translational Immunology and Research Center for Immunotherapy FZI, University Medical Center, Johannes Gutenberg University, Mainz, Germany Celiac Center, Beth Israel Deaconess Medical Center, and Harvard Celiac Center, Harvard Medical School, Boston, MA, USA Electronic address
    Best Pract Res Clin Gastroenterol 29:469-76. 2015
  3. doi request reprint Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
    Detlef Schuppan
    Molecular and Translational Medicine, University Medical Center, Johannes Gutenberg University, Mainz, Germany
    J Gastroenterol Hepatol 28:68-76. 2013
  4. pmc Evolving therapies for liver fibrosis
    Detlef Schuppan
    Institute of Molecular and Translational Medicine and Department of Medicine I, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
    J Clin Invest 123:1887-901. 2013
  5. doi request reprint Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis
    Raza Malik
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Gastroenterol Hepatol 25:1562-8. 2010
  6. pmc Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease
    Daniel Leffler
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Gut 62:996-1004. 2013
  7. pmc Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis
    Miroslaw Kornek
    Harvard Medical School, Boston, MA, USA
    Gastroenterology 143:448-58. 2012
  8. pmc Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis
    Shaoyong Li
    Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 56:2094-105. 2012
  9. pmc Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice
    Yury Popov
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 140:1642-52. 2011
  10. pmc Open conformation tissue transglutaminase testing for celiac dietary assessment
    Kumar Pallav
    The Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Dig Liver Dis 44:375-8. 2012

Collaborators

Detail Information

Publications37

  1. doi request reprint Anti-fibrotic therapy: lost in translation?
    Detlef Schuppan
    Division of Molecular and Translational Medicine, Dept of Medicine I, University of Mainz Medical School, Mainz, Germany
    J Hepatol 56:S66-74. 2012
    ..Moreover, upcoming novel biomarkers and imaging technologies will soon permit a more exact and efficient assessment of fibrosis progression and regression...
  2. doi request reprint Non-celiac wheat sensitivity: differential diagnosis, triggers and implications
    Detlef Schuppan
    Institute for Translational Immunology and Research Center for Immunotherapy FZI, University Medical Center, Johannes Gutenberg University, Mainz, Germany Celiac Center, Beth Israel Deaconess Medical Center, and Harvard Celiac Center, Harvard Medical School, Boston, MA, USA Electronic address
    Best Pract Res Clin Gastroenterol 29:469-76. 2015
    ..With oral ingestion they costimulate antigen presenting cells and promote T cell activation in celiac disease, but also in other immune-mediated diseases within and outside the GI tract. ..
  3. doi request reprint Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
    Detlef Schuppan
    Molecular and Translational Medicine, University Medical Center, Johannes Gutenberg University, Mainz, Germany
    J Gastroenterol Hepatol 28:68-76. 2013
    ..Here, we highlight the aspects of NAFLD epidemiology and pathophysiology that are beginning to lead to novel pharmacological approaches to address this growing health-care challenge...
  4. pmc Evolving therapies for liver fibrosis
    Detlef Schuppan
    Institute of Molecular and Translational Medicine and Department of Medicine I, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
    J Clin Invest 123:1887-901. 2013
    ..We also touch upon relevant clinical study endpoints, optimal study design, and developments in fibrosis imaging and biomarkers...
  5. doi request reprint Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis
    Raza Malik
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Gastroenterol Hepatol 25:1562-8. 2010
    ..We therefore compared liver stiffness by transient elastography, APRI score, AST/ALT ratio, hyaluronic acid and clinical signs to determine which modality performed best at identifying compensated cirrhosis...
  6. pmc Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease
    Daniel Leffler
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Gut 62:996-1004. 2013
    ..Lack of data regarding the kinetics of responses to gluten is a limitation in clinical practice and research when GC is performed...
  7. pmc Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis
    Miroslaw Kornek
    Harvard Medical School, Boston, MA, USA
    Gastroenterology 143:448-58. 2012
    ..Patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) can be differentiated from those with CHC based on activation of distinct sets of immune cells in the liver...
  8. pmc Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis
    Shaoyong Li
    Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 56:2094-105. 2012
    ..46, P = 0.05). In addition, supernatants from HCV-stimulated IHL of slow progressors specifically increased fibrolytic gene expression in HSC and treatment with anti-TGFβ mAb abrogated such expression...
  9. pmc Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice
    Yury Popov
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 140:1642-52. 2011
    ..We studied the contribution of TG2 to hepatic fibrotic matrix stability, as well as liver fibrosis progression and regression in TG2-deficient mice...
  10. pmc Open conformation tissue transglutaminase testing for celiac dietary assessment
    Kumar Pallav
    The Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Dig Liver Dis 44:375-8. 2012
    ..Anti tissue-transglutaminase antibody is the mainstay of celiac disease serologic testing. Whilst it has high sensitivity in patients on an unrestricted diet, sensitivity is poor for evaluation of gluten free diet adherence...
  11. pmc Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation
    Kaori Kuramitsu
    Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Pathol 183:182-94. 2013
    ..Targeting the fibrogenic progenitor response represents a promising strategy to improve hepatectomy outcomes in patients with liver fibrosis...
  12. pmc CFTR dysfunction predisposes to fibrotic liver disease in a murine model
    Camilia R Martin
    Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Physiol Gastrointest Liver Physiol 303:G474-81. 2012
    ....
  13. doi request reprint Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP
    Jörn M Schattenberg
    Department of Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
    Am J Physiol Gastrointest Liver Physiol 303:G498-506. 2012
    ..Thus predisposition to liver injury involving increased hepatocellular apoptosis is a critical mediator of accelerated fibrogenesis, and prevention of liver injury will be a most important measure for patients with chronic liver disease...
  14. doi request reprint The incidence and clinical spectrum of refractory celiac disease in a north american referral center
    Bakht Roshan
    Department of Gastroenterology, Celiac Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Gastroenterol 106:923-8. 2011
    ..However, disease patterns may be different in North America. The aim of this study was to explore the clinical spectrum of RCD in a North American population...
  15. pmc Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4
    Yvonne Junker
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Exp Med 209:2395-408. 2012
    ..These findings define cereal ATIs as novel contributors to celiac disease. Moreover, ATIs may fuel inflammation and immune reactions in other intestinal and nonintestinal immune disorders...
  16. ncbi request reprint The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease
    Raza Malik
    Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Suite 4A, Boston, Massachusetts, USA
    J Gastroenterol Hepatol 24:564-8. 2009
    ..We identified patients with nonalcoholic fatty liver disease (NAFLD) to determine the predictive value of serum markers to diagnose histological steatohepatitis (NASH)...
  17. pmc Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis
    Yury Popov
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Am J Physiol Gastrointest Liver Physiol 298:G323-34. 2010
    ....
  18. pmc Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice
    Vincent E de Meijer
    Department of Surgery and Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e11256. 2010
    ..We hypothesized that treatment with a broad-spectrum MMP and TACE-inhibitor (Marimastat) would ameliorate injury and inflammation, leading to decreased fibrogenesis during repeated hepatotoxin-induced liver injury...
  19. doi request reprint The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
    Detlef Schuppan
    Beth Israel Deaconess Medical Center, Division of Gastroenterology, Harvard Medical School, Boston, MA 02215, USA
    Liver Int 30:795-808. 2010
    ..Combined with a better understanding of the pathophysiological processes that underlie the mechanisms of hepatic fibrogenesis in NASH, rapid clinical validation of novel therapies is expected...
  20. pmc Celiac crisis is a rare but serious complication of celiac disease in adults
    Shailaja Jamma
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 8:587-90. 2010
    ..To improve awareness of this condition and to facilitate diagnosis, we reviewed cases of celiac crisis to identify presenting features, formulate diagnostic criteria, and develop treatment strategies...
  21. doi request reprint Celiac disease: from pathogenesis to novel therapies
    Detlef Schuppan
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Gastroenterology 137:1912-33. 2009
    ..These and other experimental therapies will be discussed critically...
  22. doi request reprint Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma
    Shuhei Yoshida
    Division of Gastroenterology and Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    Hepatology 58:1667-80. 2013
    ..Blocking Erk1/2 reduced proliferation and EMT-like changes of heat-treated HCC cells. Implantation of heat-exposed HEPG2 cells into nude mice induced significantly larger, more aggressive tumors than untreated cells...
  23. doi request reprint Update on serologic testing in celiac disease
    Daniel A Leffler
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Gastroenterol 105:2520-4. 2010
    ..We discuss the need to develop tests for CD activity in order to assess the efficacy of upcoming nondietary therapies...
  24. pmc Increased plasma levels of microparticles expressing CD39 and CD133 in acute liver injury
    Moritz Schmelzle
    The Transplant Institute and Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA
    Transplantation 95:63-9. 2013
    ..Here, we tested whether CD133 MP might be shed in a CD39-dependent manner in a model of liver injury and could potentially serve as biomarkers of liver failure in the clinic...
  25. doi request reprint Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies
    Yury Popov
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Hepatol 48:453-64. 2008
    ..We studied alphavbeta6 expression in experimental and human liver fibrosis and the potential of its pharmacological inhibition for treatment of hepatic fibrosis...
  26. doi request reprint Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies
    Yury Popov
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Hepatology 50:1294-306. 2009
    ..The availability of such noninvasive methodologies will serve as the pacemaker for the clinical development and validation of potent antifibrotic agents...
  27. doi request reprint Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice
    Shuhei Yoshida
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    Gastroenterology 147:1378-92. 2014
    ..We studied the cellular sources of PDGFB and the effects of a high-affinity monoclonal antibody against PDGFB (MOR8457) in mouse models of biliary fibrosis...
  28. doi request reprint Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis
    Carolina Jiménez Calvente
    Institute of Translational Immunology, University of Mainz Medical Center, Mainz, Germany
    Hepatology 62:1285-97. 2015
    ....
  29. doi request reprint Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic
    Jörn M Schattenberg
    Department of Medicine I bCenter for Molecular and Translational Medicine, University Medical Center of the Johannes Gutenberg University, Langenbeckstrase 1, Mainz, Germany
    Curr Opin Lipidol 22:479-88. 2011
    ....
  30. doi request reprint Salivary proline-rich proteins and gluten: Do structural similarities suggest a role in celiac disease?
    Na Tian
    Department of Molecular and Cell Biology, Boston University Henry M Goldman School of Dental Medicine, Boston, MA, USA
    Proteomics Clin Appl 9:953-64. 2015
    ..Both are enriched in proline and glutamine residues that often occur consecutively in their sequences. We investigated potential differences in the spectrum of salivary PRPs in health and CD...
  31. pmc Liver cirrhosis
    Detlef Schuppan
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 371:838-51. 2008
    ..This Seminar focuses on the diagnosis, complications, and management of cirrhosis, and new clinical and scientific developments...
  32. pmc Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets
    Ffolliott M Fisher
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts Electronic address
    Gastroenterology 147:1073-83.e6. 2014
    ....
  33. doi request reprint Nondietary therapies for celiac disease
    Rupa Mukherjee
    Department of Medicine, Division of Gastroenterology, The Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Gastrointest Endosc Clin N Am 22:811-31. 2012
    ..These novel strategies provide promise of alternative, adjunctive treatment options but also raise important questions regarding safety, efficacy, and monitoring of long-term treatment effect...
  34. doi request reprint Nonceliac gluten sensitivity
    Alessio Fasano
    Mucosal Immunology and Biology Research Center and Center for Celiac Research, Massachusetts General Hospital for Children, Harvard Medical School, Boston, Massachusetts Electronic address
    Gastroenterology 148:1195-204. 2015
    ..We review the most recent findings on NCGS and outline directions to dissipate some of the confusion related to this disorder. ..
  35. doi request reprint A validated disease-specific symptom index for adults with celiac disease
    Daniel A Leffler
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Gastroenterol Hepatol 7:1328-34, 1334.e1-3. 2009
    ..Although the incidence of celiac disease (CD) is increasing, studies have been hampered by the lack of validated outcome measures. We sought to create a disease-specific Celiac Symptom Index (CSI) to reliably assess relevant symptoms...
  36. doi request reprint Wheat amylase trypsin inhibitors as nutritional activators of innate immunity
    Detlef Schuppan
    Institute for Translational Immunology and Research Center for Immunotherapy, University Medical Center, Johannes Gutenberg University, Mainz, Germany
    Dig Dis 33:260-3. 2015
    ..Thus, ATIs may be prime candidates of severe forms of non-celiac gluten (wheat) sensitivity...
  37. pmc HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB
    Wenyu Lin
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Biol Chem 286:2665-74. 2011
    ..Strategies to limit the viral induction of oxidative stress are warranted to inhibit fibrogenesis...